Trials / Completed
CompletedNCT04253626
Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the extent to which treatment of iron deficiency anemia beyond 24-34 weeks' gestation of pregnancy with intravenous iron increases hemoglobin compared to oral iron. The investigators will test the hypothesis that pregnant women who are anemic in the second and third trimester are more likely to significantly increase their hemoglobin with intravenous iron as opposed to the usual standard of care, oral iron.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferumoxytol Injection [Feraheme] | 510mg intravenous ferumoxytol |
| DRUG | Ferrous Sulfate | 325mg oral ferrous sulfate |
Timeline
- Start date
- 2021-01-21
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
- First posted
- 2020-02-05
- Last updated
- 2025-08-26
- Results posted
- 2025-08-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04253626. Inclusion in this directory is not an endorsement.